Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620368
Title:
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Authors:
Earl, H. M.; Hiller, L.; Howard, H. C.; Dunn, J. A.; Young, J.; Bowden, S. J.; McDermaid, M.; Waterhouse, A. K.; Wilson, G.; Agrawal, R.; O'Reilly, S.; Bowman, A.; Ritchie, D.M.; Goodman, Andrew; Hickish, T.; McAdam, K.; Cameron, D.; Dodwell, D.; Rea, D. W.; Caldas, C.; Provenzano, E.; Abraham, J. E.; Canney, P.; Crown, J. P.; Kennedy, M. J.; Coleman, R.; Leonard, R. C.; Carmichael, J. A.; Wardley, A. M.; Poole, C. J.
Abstract:
The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.
Citation:
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. 2017, 18 (6):755-769 Lancet Oncol.
Publisher:
Elsevier
Journal:
The Lancet. Oncology
Issue Date:
Jun-2017
URI:
http://hdl.handle.net/11287/620368
DOI:
10.1016/S1470-2045(17)30319-4
PubMed ID:
28479233
Additional Links:
https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30319-4
Type:
Journal Article
Project details (details from EDGE):
EDGE Project ID: 38
Language:
en
ISSN:
1474-5488
Sponsors:
University of Birmingham
Appears in Collections:
Oncology; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorEarl, H. M.en
dc.contributor.authorHiller, L.en
dc.contributor.authorHoward, H. C.en
dc.contributor.authorDunn, J. A.en
dc.contributor.authorYoung, J.en
dc.contributor.authorBowden, S. J.en
dc.contributor.authorMcDermaid, M.en
dc.contributor.authorWaterhouse, A. K.en
dc.contributor.authorWilson, G.en
dc.contributor.authorAgrawal, R.en
dc.contributor.authorO'Reilly, S.en
dc.contributor.authorBowman, A.en
dc.contributor.authorRitchie, D.M.en
dc.contributor.authorGoodman, Andrewen
dc.contributor.authorHickish, T.en
dc.contributor.authorMcAdam, K.en
dc.contributor.authorCameron, D.en
dc.contributor.authorDodwell, D.en
dc.contributor.authorRea, D. W.en
dc.contributor.authorCaldas, C.en
dc.contributor.authorProvenzano, E.en
dc.contributor.authorAbraham, J. E.en
dc.contributor.authorCanney, P.en
dc.contributor.authorCrown, J. P.en
dc.contributor.authorKennedy, M. J.en
dc.contributor.authorColeman, R.en
dc.contributor.authorLeonard, R. C.en
dc.contributor.authorCarmichael, J. A.en
dc.contributor.authorWardley, A. M.en
dc.contributor.authorPoole, C. J.en
dc.date.accessioned2017-07-20T13:12:42Z-
dc.date.available2017-07-20T13:12:42Z-
dc.date.issued2017-06-
dc.identifier.citationAddition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. 2017, 18 (6):755-769 Lancet Oncol.en
dc.identifier.issn1474-5488-
dc.identifier.pmid28479233-
dc.identifier.doi10.1016/S1470-2045(17)30319-4-
dc.identifier.urihttp://hdl.handle.net/11287/620368-
dc.description.abstractThe tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.en
dc.description.sponsorshipUniversity of Birminghamen
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30319-4en
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleAddition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.en
dc.typeJournal Articleen
dc.identifier.journalThe Lancet. Oncologyen
dc.description.fundingBristol-Myers Squibben
dc.type.versionPublisheden
dc.description.projectreferencenumberEDGE Project ID: 38en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.